Navneet Verma, managing director and CEO, Kayem Pharmaceuticals, has assured Reprieve, a United Kingdom-based provider of legal assistance to prisoners who cannot fend for themselves, that no Indian manufacturer will sell thiopental sodium -- an ingredient used in lethal injections by US Correctional Services -- to jails in the United States that use it for lethal purposes.
The other Indian manufacturers include big names like Maharashtra (Andheri)-headquartered Neon Laboratories; Ahmedabad-based Swiss Pharma; and Noida-based Jagson Pharmaceuticals.
However, these three companies do not sell the molecule directly to US jails.
Verma assured Reprieve investigator Sophie Walker at his office in the north Mumbai suburb of Borivali that not only Kayem but all other manufacturers of thiopental sodium have decided not to sell it to US jails.
However, he warned Walker that any use of intimidating language or action by Reprieve against his company would not be tolerated.
Kayem Pharma's sale of thiopental sodium to the states of South Dakota and Nebraska were in the eye of a storm after Reprieve took up cudgels with the Indian manufacturer when a lawyer in Nebraska moved a local court for use of the molecule from India-based Kayem.
Click NEXT to read on . . .
this
Users
Comment
article